Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL11024488 | 0.98 | ESR2 (0.57) | ESR2HSD11B1CYP1A2SUCNR1NOTUM | |
| SCHEMBL12497363 | 0.89 | NOTUM (0.48) | ESR2HSD11B1CYP1A2NOTUMSLC1A3 | |
| Ether SCHEMBL11024485 | 0.88 | ESR2 (0.47) | ESR2HSD11B1CYP1A2SUCNR1NOTUM | |
| SCHEMBL30487478 | 0.86 | NOTUM (0.47) | ESR2HSD11B1CYP1A2NOTUMSLC1A3 | |
| SCHEMBL680179 | 0.86 | NOTUM (0.47) | ESR2HSD11B1CYP1A2NOTUMSLC1A3 | |
| SCHEMBL13494486 | 0.83 | NOTUM (0.44) | ESR2HSD11B1NOTUMKMT2AMEN1 | |
| SCHEMBL10388611 | 0.83 | CYP1A2 (0.46) | ESR2HSD11B1CYP1A2SUCNR1KMT2A | |
| SCHEMBL29719717 | 0.81 | NOTUM (0.53) | HSD11B1NOTUMGRM2TP53CYP2A6 | |
| SCHEMBL27395925 | 0.81 | NOTUM (0.43) | ESR2HSD11B1NOTUMKMT2AMEN1 | |
| SCHEMBL30984364 | 0.80 | NPC1 (0.49) | CYP1A2NOTUMGRM2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102010317-B | Method for synthesizing felbinac and derivatives thereof | USTC UNIV SCIENCE TECH CN | 2013-10-16 | — | — | CN | claimed |
| US-7271183-B2 | 2-Piperidone derivatives as prostaglandin agonists | ROCHE PALO ALTO LLC (US) | 2007-09-18 | — | — | US | claimed |
| EP-0979809-B1 | Process for the preparation of 4-chlorobiphenylenes | CLARIANT GMBH (DE) | 2003-01-29 | — | — | EP | claimed |
| US-6066766-A | Process for the preparation of 4-chlorobiphenyls | CLARIANT GMBH (DE) | 2000-05-23 | — | — | US | claimed |
| EP-0979809-A1 | Process for the preparation of 4-chlorobiphenylenes | Clariant GmbH (DE) | 2000-02-16 | — | — | EP | claimed |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| EP-3988549-A1 | MACROCYCLES WITH HETEROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2021-07-08 | — | — | US | disclosed |
| US-11053247-B2 | Pyrimidinones as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-06 | — | — | US | disclosed |
| US-11040966-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-06-22 | — | — | US | disclosed |
| US-20200055854-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-20 | — | — | US | disclosed |
| EP-1233009-A2 | Method for production of 4-substituted 2-alkylbiphenyls and 2-alcoxybiphenyls | Clariant GmbH (DE) | 2002-08-21 | — | — | EP | disclosed |
| US-6066766-A | Process for the preparation of 4-chlorobiphenyls | CLARIANT GMBH (DE) | 2000-05-23 | — | — | US | disclosed |
| CN-1252713-A | N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID CO (US) | 2000-05-10 | — | — | CN | disclosed |
| JP-2000095713-A | PRODUCTION OF 4-CHLOROBIPHENYL | CLARIANT GMBH | 2000-04-04 | — | — | JP | disclosed |
| EP-0979809-A1 | Process for the preparation of 4-chlorobiphenylenes | Clariant GmbH (DE) | 2000-02-16 | — | — | EP | disclosed |
| US-4431660-A | UROGENITAL DISORDERS; ENZYME INHIBITORS; KIDNEY AND BLADDER STONES | MERCK & CO., INC. (US) | 1984-02-14 | — | — | US | disclosed |
| US-4256758-A | 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase | MERCK & CO., INC. (US) | 1981-03-17 | — | — | US | disclosed |
| US-4221803-A | FUNGICIDES, BACTERICIDES | RECORDATI, S.A. (CH) | 1980-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053247-B2 | Pyrimidinones as factor XIA inhibitors | TFPI, TFPI2, F11 | ESR2 2584/4885HSD11B1 903/4885CYP1A2 857/4885 |
| US-20200055854-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | ESR2 2584/4885HSD11B1 903/4885CYP1A2 857/4885 |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | ESR2 2059/4885HSD11B1 43/4885CYP1A2 137/4885 |
| US-11040966-B2 | Benzimidazole-proline derivatives | HCRTR1, HCRTR2, NPY1R | ESR2 921/4885HSD11B1 1803/4885CYP1A2 754/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | ESR2 2059/4885HSD11B1 43/4885CYP1A2 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.